The partnership with Sirius expands CRISPR Therapeutics’ modality toolkit, especially in the cardiovascular space.

The strategic partnership is likely to diversify CRISPR Therapeutics’ pipeline by adding Sirius’s lead candidate, SRSD107, a next-generation, long-acting siRNA therapy, which is being ...

SAN DIEGO & SHANGHAI, May 09, 2025--(BUSINESS WIRE)--Sirius Therapeutics ... clinical programs and expand our pipeline, to deliver "transformative siRNA therapeutics for patients with chronic ...

Sirius Therapeutics today announced that it has ... this round will further advance our clinical programs and expand our pipeline, to deliver “transformative siRNA therapeutics for patients ...

CRISPR Therapeutics CRSP announced that it has entered into a collaboration deal with San Diego-based privately held company, Sirius Therapeutics, for developing and commercializing novel siRNA ...

CRISPR Therapeutics and Sirius Therapeutics have formed a strategic ... clinical trials and pipeline products and programs, including, without limitation, expectations regarding data, safety ...

Sirius’ siRNA platform complements ... any or all of the following: (i) CRISPR Therapeutics preclinical studies, clinical trials and pipeline products and programs, including, without limitation ...

Learn about May 2025’s top biotech deals, featuring major collaborations in RNA interference technology, small molecules, and ...